The FDA’s ISTAND Pilot Program has been elevated as a permanent qualification program, allowing for tools such as micro-physiological systems (“organ-on-a-chip”), AI-driven in vitro platforms, and digital endpoints to be qualified as Drug Development Tools (DDTs). If you’re developing or deploying NAMs (new-approach methodologies), early alignment with the ISTAND/qualification pathway is essential.